Forest plot for hs-CRP. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for IL-6. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

The incidence rate of adverse reactions. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

The PRISMA study flowchart. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for clinical efficacy. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

The excluded and included studies were listed. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for PaCO₂. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for PaO₂. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Data Sheet 1_2D speckle-tracking echocardiography assessment of left atrial and left ventricular mechanics: outcomes in patients with atrial fibrillation treated with hybrid ablati... by Andrea Maria Paparella (20865617)

“…</p>Results<p>A total of 50 patients were included. At follow-up, LAEDV decreased from baseline [44.7 mL vs 53.8 mL, P = 0.025]. …”

Data Sheet 1_Exploring the therapeutic potential of “Zhi-Zhen” formula for oxaliplatin resistance in colorectal cancer: an integrated study combining UPLC-QTOF-MS/MS, bioinformatic... by Yongjing Li (3821944)

“…Background<p>Chemoresistance is a critical factor compromising the survival of patients with colorectal cancer (CRC). …”

Supporting information. by Maedehsadat Seyedalangi (22655973)

“…<div><p>The study aimed to evaluate the impact of gliding arc plasma (GAP) treatment and phycocyanin pigment (PCP) on the antioxidant activity and refrigerated shelf-life extension of <i>Oncorhynchus mykiss</i> (rainbow trout) fillets (OMR) during 18 days of storage at 4 ± 0.1 °C. …”

Data Sheet 1_Premature renal epithelial cell senescence promoted by LXN/Rps3/p53 signaling pathway activation increases calcium oxalate crystal deposition by altering macrophage po... by Maolin Chu (11611507)

“…Furthermore, reducing cellular LXN/Rps3/p53 signaling significantly decreased SASP factors in the culture medium and simultaneously abolished M1-like phenotype macrophage polarization. …”

Data Sheet 7_Global, regional, and national burdens of pancreatitis in children and adolescents aged 0–24 years from 1992 to 2021: a trend analysis based on the global burden of di... by Ying-han Deng (21604157)

“…Background<p>The younger onset of pancreatitis presents a significant public health challenge. This study aims to analyze the global burden of pancreatitis in younger populations based on the Global Burden of Disease 2021.…”

Data Sheet 3_Global, regional, and national burdens of pancreatitis in children and adolescents aged 0–24 years from 1992 to 2021: a trend analysis based on the global burden of di... by Ying-han Deng (21604157)

“…Background<p>The younger onset of pancreatitis presents a significant public health challenge. This study aims to analyze the global burden of pancreatitis in younger populations based on the Global Burden of Disease 2021.…”

Data Sheet 4_Global, regional, and national burdens of pancreatitis in children and adolescents aged 0–24 years from 1992 to 2021: a trend analysis based on the global burden of di... by Ying-han Deng (21604157)

“…Background<p>The younger onset of pancreatitis presents a significant public health challenge. This study aims to analyze the global burden of pancreatitis in younger populations based on the Global Burden of Disease 2021.…”

Data Sheet 6_Global, regional, and national burdens of pancreatitis in children and adolescents aged 0–24 years from 1992 to 2021: a trend analysis based on the global burden of di... by Ying-han Deng (21604157)

“…Background<p>The younger onset of pancreatitis presents a significant public health challenge. This study aims to analyze the global burden of pancreatitis in younger populations based on the Global Burden of Disease 2021.…”

Data Sheet 8_Global, regional, and national burdens of pancreatitis in children and adolescents aged 0–24 years from 1992 to 2021: a trend analysis based on the global burden of di... by Ying-han Deng (21604157)

“…Background<p>The younger onset of pancreatitis presents a significant public health challenge. This study aims to analyze the global burden of pancreatitis in younger populations based on the Global Burden of Disease 2021.…”

Data Sheet 2_Global, regional, and national burdens of pancreatitis in children and adolescents aged 0–24 years from 1992 to 2021: a trend analysis based on the global burden of di... by Ying-han Deng (21604157)

“…Background<p>The younger onset of pancreatitis presents a significant public health challenge. This study aims to analyze the global burden of pancreatitis in younger populations based on the Global Burden of Disease 2021.…”

Data Sheet 5_Global, regional, and national burdens of pancreatitis in children and adolescents aged 0–24 years from 1992 to 2021: a trend analysis based on the global burden of di... by Ying-han Deng (21604157)

“…Background<p>The younger onset of pancreatitis presents a significant public health challenge. This study aims to analyze the global burden of pancreatitis in younger populations based on the Global Burden of Disease 2021.…”

Data Sheet 2_Antimycobacterial and immunomodulatory activities of sorafenib in a preclinical mouse model of TB infection through CD4+CD25low and CD8+CD25low effector T cells.pdf by Raju S. Rajmani (11134060)

“…It is one of the major global public health problems that leads to a high morbidity and mortality rate. …”